|
Palo Alto, CA - March 9, 2004 — Telik, Inc. (Nasdaq:
TELK) announced the initiation of a multicenter Phase 1-2a clinical
trial in which TELCYTA™ (TLK286) will be evaluated in combination
with platinum in the front-line treatment of Stage IIIb or IV non-small
cell lung cancer (NSCLC). The trial is expected to enroll approximately
50 NSCLC patients who have not previously received chemotherapy.
Platinum is the current mainstay of front-line metastatic lung cancer
treatment.
The trial is based upon the clinical results reported at the AACR-NCI-EORTC
meeting in November 2003 in which TELCYTA demonstrated the ability
to contribute to platinum-based chemotherapy without unanticipated
toxicities.
About Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer deaths in men and women
in the United States, according to the American Cancer Society (ACS).
The ACS estimates that more than 173,000 new cases of lung cancer
will be diagnosed in 2004 and an estimated 160,400 deaths will result
from the disease, representing approximately 28% of all cancer deaths
in the U.S.
About TELCYTA™ and TELCYTA™ Clinical
Trials
A Phase 3 registration trial is ongoing using TELCYTA™ as
a single agent in the treatment of ovarian cancer, and a Phase 3
registration trial is expected to begin in the near future in the
treatment of NSCLC. Click here
for further information on TELCYTA™ trials.
TELCYTA™ is a small molecule tumor-activated drug which is
activated by an enzyme present in higher levels in many human cancers
than in normal tissues. Upon activation, an intracellular process
known as apoptosis, or programmed cell death, is initiated. TELCYTA™,
which has been evaluated in clinical trials in ovarian, NSCLC, breast
and colorectal cancer, was discovered through the application of
Telik’s proprietary drug discovery technology, TRAP.
About Telik
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize innovative small molecule
drugs to treat serious diseases. The company’s most advanced
drug development candidate is TELCYTA™ (TLK286), a tumor-activated
small molecule product candidate that is in a Phase 3 registration
trial in advanced ovarian cancer and in Phase 2 clinical trials
in ovarian, non-small cell lung and breast cancer. Telik’s
product candidates were discovered using its proprietary drug discovery
technology, TRAP, which enables the rapid and efficient discovery
of small molecule drug candidates. Additional information is available
at www.telik.com.
This press release contains “forward-looking” statements.
For this purpose, any statements contained in this press release
that are not statements of historical fact may be deemed to be forward-looking
statements, including any statements regarding the potential for
TELCYTA™ (TLK286) or TELINTRA™ (TLK199) to treat one
or more types of cancer. There are a number of important factors
that could cause Telik's results to differ materially from those
indicated by these forward-looking statements, including, among
others, the following: none of Telik’s product candidates,
including TELCYTA™, has been determined to be safe or effective
in humans or received regulatory approval for marketing; it may
take us several years to complete clinical trials of our product
candidates, including TELCYTA™, prior to seeking regulatory
approval for any indication; success in preclinical testing and
early clinical trials does not ensure that later clinical trials
will be successful, and interim results of clinical trials do not
necessarily predict final results; if our competitors develop and
market products that are more effective than our product candidates,
or obtain regulatory approval before we do, our commercial opportunity
will be reduced or eliminated; if we do not obtain regulatory approval
to market products in the United States and foreign countries, we
will not be permitted to commercialize our product candidates; if
we are unable to contract with third parties to manufacture our
product candidates in sufficient quantities and at an acceptable
cost, clinical development of product candidates could be delayed;
and if we are unable to raise adequate funds in the future, we will
not be able to continue to fund our operations and clinical trials
to develop our product candidates. These and other risks are detailed
from time to time in our SEC reports, including our Annual Report
on Form 10-K for the year ended December 31, 2003. Telik does not
undertake any obligation to update forward-looking statements.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2004
Press Releases2003
Press ReleasesEvents
|
